Return on Retained Earnings (RORE) is an indicator of a company's growth potential, it shows how much a company earns by reinvesting its retained earnings, i.e. profits after dividend payments.
Corcept Therapeutics's 3-Year RORE % for the quarter that ended in Mar. 2026 was -28.98%.
The industry rank for Corcept Therapeutics's 3-Year RORE % or its related term are showing as below:
HAM:HTD's 3-Year RORE % is ranked worse than 66.62% of 1294
companies
in the Biotechnology industry
Industry Median: -11.54
vs HAM:HTD: -28.98
Return on Retained Earnings (RORE) is important to investors because it reveals a company's efficiency and growth potential. A higher RORE indicates a higher return. A high RORE indicates that the company should reinvest profits into the business. A lower RORE suggests that the company should distribute profits to shareholders by paying out dividends, since those dollars aren't generating much additional growth for the company.
There are a several different ways to arrive at the Return on Retained Earnings. The simplest way to calculate it is by using published information on Earnings per Share (EPS) and Dividend per Share (DPS) over a selected period. Here, 3-year period is chosen.
Be Aware
Please keep in mind that the RORE is relative to the nature of the business and its competitors. If another company in the same sector is producing a lower return on retained earnings, it doesn’t necessarily mean it’s a bad investment. It may just suggest the company is older and no longer in a high growth stage. At such a stage in the business cycle, it would be expected to see a lower RORE and higher dividend payout.
Corcept Therapeutics 3-Year RORE % Related Terms
Corcept Therapeutics 3-Year RORE % Historical Data
* Premium members only.
The historical data trend for Corcept Therapeutics's 3-Year RORE % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
HAM:HTD vs PRAX, IBRX, NUVL: 3-Year RORE % Comparison
For the Biotechnology subindustry, Corcept Therapeutics's 3-Year RORE %, along with its competitors' market caps and 3-Year RORE % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Corcept Therapeutics 3-Year RORE % vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Corcept Therapeutics's 3-Year RORE % distribution charts can be found below:
* The bar in red indicates where Corcept Therapeutics's 3-Year RORE % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
In the calculation of 3-Year RORE %, the most recent and first period EPS (Diluted) is the trailing twelve months (TTM) data ended in Mar. 2026 and 3-year before.
Corcept Therapeutics (HAM:HTD) has a 3-Year RORE % of -28.98 as of Mar. 2026. 3-Year RORE % shows how much a company earns by reinvesting its retained earnings in 3-year. View historical data on Corcept Therapeutics and its competitors. According to the industry distribution chart, Corcept Therapeutics ranks #862 out of 1294 companies in the Biotechnology industry, placing it in the top 66.6%.
Is Corcept Therapeutics' 3-Year RORE % too high?
Corcept Therapeutics' current 3-Year RORE % is -28.98. Based on the distribution chart, Corcept Therapeutics ranks #862 out of 1294 companies in the Biotechnology industry, which is below the industry midpoint. Overall, Corcept Therapeutics has a GF Score™ of 88/100, reflecting its overall financial health beyond just this single metric.
How does Corcept Therapeutics' 3-Year RORE % compare to PRAX and IBRX?
According to the Biotechnology industry distribution chart, Corcept Therapeutics ranks #862 out of 1294 companies for 3-Year RORE %. This places Corcept Therapeutics in the lower half of its industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good 3-Year RORE % for a Biotechnology company?
A good 3-Year RORE % depends on the Biotechnology industry context. However, 3-Year RORE % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high 3-Year RORE % mean?
A high 3-Year RORE % can signal that a stock is expensive relative to its fundamentals. 3-Year RORE % shows how much a company earns by reinvesting its retained earnings in 3-year. View historical data on Corcept Therapeutics and its competitors. Corcept Therapeutics's current 3-Year RORE % is -28.98. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Corcept Therapeutics stock overvalued right now?
Corcept Therapeutics (HAM:HTD) has a current 3-Year RORE % of -28.98. The stock's GF Value™ is €55.15, compared to a current price of €77.20 — trading 40% above its estimated fair value. The current 3-Year RORE % is -28.98. Corcept Therapeutics' overall GF Score™ is 88/100 with 8 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is 3-Year RORE % calculated?
3-Year RORE % is calculated from a company's financial statements. For Corcept Therapeutics (HAM:HTD), the current 3-Year RORE % is -28.98 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Corcept Therapeutics (HAM:HTD) Overvalued in 2026?
Based on GuruFocus' analysis, Corcept Therapeutics stock appears to be overvalued.
The current stock price of €77.20 is trading 40% above its estimated GF Value™ of €55.15.
Key valuation signals for HAM:HTD:
3-Year RORE %: -28.98
GF Value™: €55.15 vs. price of €77.20 (40% above fair value)
No single metric tells the full story. See the HAM:HTD stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Corcept Therapeutics Inc is a commercial-stage pharmaceutical company engaged in the discovery and development of medications that treat severe metabolic, oncologic, and neuropsychiatric disorders by modulating the effect of the cortisol hormone. The company markets Korlym (mifepristone) tablets and its authorized generic version, which is an oral medication for the treatment of hypercortisolism (also known as Cushing's syndrome). Additionally, its pipeline contains several key compounds, such as Relacorilant, Dazucorilant, Miricorilant, etc., that are being evaluated in clinical trials as potential treatments for a variety of serious disorders like hypercortisolism, solid tumors (including ovarian, endometrial, cervical, pancreatic, and prostate cancers), ALS, and MASH.
88GF Score
Get the complete analysis for HAM:HTD
3-Year RORE % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
HAM:HTD has been successfully added to your 
